AstraZeneca
AZN
398 hedge funds and large institutions have $8.72B invested in AstraZeneca in 2016 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 154 increasing their positions, 98 reducing their positions, and 38 closing their positions.
225% more call options, than puts
Call options by funds: $99.3M | Put options by funds: $30.6M
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
57% more repeat investments, than reductions
Existing positions increased: 154 | Existing positions reduced: 98
32% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 38
20% more capital invested
Capital invested by funds: $7.26B → $8.72B (+$1.46B)
2% more funds holding
Funds holding: 390 → 398 (+8)
1.22% more ownership
Funds ownership: 10.2% → 11.42% (+1.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$214M |
| 2 |
Dodge & Cox
San Francisco,
California
|
+$188M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$120M |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$108M |
| 5 |
BIM
BlackRock Investment Management
Wilmington,
Delaware
|
+$88.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$66.5M |
| 2 |
Jennison Associates
New York
|
-$63.3M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$37.9M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$22.3M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$18.5M |
AZN Hedge Fund Activity: Q2 2016 in Review
398 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q2 2016, worth a combined $8.72B — up 20% from $7.26B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new AZN positions and 38 closed out — a net gain of 12 holders — while 154 added to existing stakes and 98 trimmed.
The largest buyer was Bank of America, adding an estimated $214M. The largest seller was Capital World Investors, cutting an estimated $66.5M.
- 398 institutional investors held AstraZeneca (AZN) as of Q2 2016, up from 390 in Q1 2016.
- Funds reported $8.72B of AstraZeneca stock for Q2 2016, up 20% quarter-over-quarter.
- 50 funds opened new AstraZeneca positions in Q2 2016 and 38 closed out, a net change of +12 holders.
- The largest AstraZeneca buyer in Q2 2016 was Bank of America, an estimated $214M added.
- The largest AstraZeneca seller in Q2 2016 was Capital World Investors, an estimated $66.5M sold.
Based on aggregated 13F filings for Q2 2016.